CRANBURY, N.J.--(BUSINESS WIRE)--Targeted Therapies in Oncology™, an oncology resource that provides oncology professionals with cutting-edge research, data, and treatment strategies surrounding molecular and immune system targets, welcomes Arjun V. Balar, M.D., as its editor-in-chief.
In this role, Balar will work closely with the editorial team to promote major targeted therapy innovations. He will also be responsible for sharing novel studies on the spectrum of cancer research and targeted therapies.
“We are thrilled to have Dr. Balar join our team,” said Michael J. Hennessy Jr., president of MJH Associates Inc., parent company of Targeted Oncology™. “His expertise from the field of oncology will help our team continue to deliver unprecedented information and data to the community.”
Dr. Balar added, “I am excited to begin this new role, leading this informative publication in providing the most current, timely and practice-changing research and oncology news coverage to the community.”
Balar is an assistant professor in the department of medicine and serves as the director of the genitourinary medical oncology program at NYU Langone’s Perlmutter Cancer Center. He primarily focuses on treating and managing genitourinary cancers, such as prostate cancer, bladder cancer, kidney cancer and testicular cancer. His research concentration includes immunotherapy and molecularly-targeted therapy.
For more information on Targeted Therapies in Oncology™, visit www.targetedonc.com.
About Targeted Oncology™
TargetedOnc.com provides the latest news and insight on next-generation therapeutics and their molecular targets for practicing oncologists. As the field of oncology continues to trend toward systemic biology and molecular aberrations, the challenge facing many oncologists is staying up-to-date with the future of cancer therapeutics. As such, TargetedOnc strives to provide the latest information on breaking news and updates on the burgeoning field. TargetedOnc focuses on the next stage of cancer development, on cutting-edge therapies and their biological targets. Content is organized by tumor type, news and conference coverage.
